Company intelligence / Profile preview

Oak Pharmaceuticals

Lake Forest, Illinois, United States

Ownership: Private
Development stage: Other

Overview

Oak Pharmaceuticals was a specialty pharmaceutical company that operated as a subsidiary of Akorn, Inc. The company specialized in the development and commercialization of niche generic and branded pharmaceutical products, with a strong focus on ophthalmology and hospital-based injectables. Its portfolio featured notable products such as Akten for ocular anesthesia and Zioptan for glaucoma. Following the Chapter 7 bankruptcy filing and subsequent liquidation of Akorn in February 2023, Oak Pharmaceuticals ceased all operations.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Oak Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oak Pharmaceuticals.

Explore the full profile